effect of amlodipine on oxidative stress markers and serum ferritin level in ß-thalassemia patients

Evaluation of the effect of amlodipine on oxidative stress markers and serum ferritin level in ß-thalassemia patients undergoing iron chelation therapy: A randomized double-blind Cross-Over study

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090613002027N16

Enrollment

Registered

2019-09-17

Start date

2019-01-09

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ß-thalassemia. Beta thalassemia

Interventions

Intervention 1: Intervention group: amlodipine tablets 5 mg daily for 6 months. Intervention 2: Control group: Amlodipine placebo daily for 6 months.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Beta-thalassemia patients with moderate to severe heart sediment (based on MRI T2 less than 15 milliseconds) Age over 18 years Written informed consent

Exclusion criteria

Exclusion criteria: Other medicines for calcium blocker (verapamil-diltiazem-cartidilol) Continuous hypotension due to heart failure Aortic valve stenosis Sinoatrial node diseas Heart failure

Design outcomes

Primary

Measure	Time frame
Oxidative stress indices (malondialdehyde, carbonyl protein and total antioxidant). Timepoint: Baseline, month 6 and month 12. Method of measurement: Laboratory analysis.	—

Secondary

Measure	Time frame
Ferritin. Timepoint: Baseline, month 6 and month 12. Method of measurement: Laboratory analysis.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactEbrahim Salehifar

Sari University of Medical Sciences

salehifare@yahoo.com+98 11 3354 3241

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026